- Home
- IRBT vs AARD Comparison
IRBT vs AARD Comparison
Compare IRBT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRBT
- AARD
- Stock Information
- Founded
- IRBT 1990
- AARD 2017
- Country
- IRBT United States
- AARD United States
- Employees
- IRBT N/A
- AARD N/A
- Industry
- IRBT Consumer Electronics/Appliances
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- IRBT Consumer Discretionary
- AARD Health Care
- Exchange
- IRBT Nasdaq
- AARD Nasdaq
- Market Cap
- IRBT 130.0M
- AARD 154.9M
- IPO Year
- IRBT N/A
- AARD 2025
- Fundamental
- Price
- IRBT $4.88
- AARD $14.70
- Analyst Decision
- IRBT Hold
- AARD Strong Buy
- Analyst Count
- IRBT 1
- AARD 5
- Target Price
- IRBT N/A
- AARD $33.00
- AVG Volume (30 Days)
- IRBT 2.9M
- AARD 76.9K
- Earning Date
- IRBT 08-05-2025
- AARD 08-14-2025
- Dividend Yield
- IRBT N/A
- AARD N/A
- EPS Growth
- IRBT N/A
- AARD N/A
- EPS
- IRBT N/A
- AARD N/A
- Revenue
- IRBT $633,404,000.00
- AARD N/A
- Revenue This Year
- IRBT $3.23
- AARD N/A
- Revenue Next Year
- IRBT $28.90
- AARD N/A
- P/E Ratio
- IRBT N/A
- AARD N/A
- Revenue Growth
- IRBT N/A
- AARD N/A
- 52 Week Low
- IRBT $1.76
- AARD $4.88
- 52 Week High
- IRBT $13.45
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- IRBT 61.53
- AARD N/A
- Support Level
- IRBT $4.28
- AARD N/A
- Resistance Level
- IRBT $5.52
- AARD N/A
- Average True Range (ATR)
- IRBT 0.54
- AARD 0.00
- MACD
- IRBT 0.07
- AARD 0.00
- Stochastic Oscillator
- IRBT 65.78
- AARD 0.00
About IRBT iRobot Corporation
iRobot Corp is a United state based consumer robot company. It designs and builds robots that assist consumers with the solutions for the activities to be carried out both inside and outside of the home. The company's consumer robot comprises a portfolio of solutions which includes cleaning, mapping and navigation, human-robot interaction, and physical solutions. The company operates in the business segment of Consumer robots. The consumer robot products are provided to the consumers by retail businesses and online stores. The company derives its revenue from the product sales. It sells the products across the United States and around the world.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.